Clinical trial · Interventional
Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining
NCT03180944CI-TRIAL-00042704completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was to test an optimal concentration of Lugol's solution which can reduce the mucosal irritation and provide high image quality to ensure endoscopy examination by a randomized blinded controlled trial.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Image Quality | — | UNRESOLVED | — |
| Mucosal Irritation | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 0.4% Lugol's solution | Drug | — | UNRESOLVED |
| 0.6% Lugol's solution | Drug | — | UNRESOLVED |
| 0.8% Lugol's solution | Drug | — | UNRESOLVED |
| 1.0% Lugol's solution | Drug | — | UNRESOLVED |
| 1.2% Lugol's solution | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- type
- EXPERIMENTAL
- label
- 1.2% Lugol's solution
- description
- This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.
- interventionNames
- Drug: 1.2% Lugol's solution
- type
- EXPERIMENTAL
- label
- 1.0% Lugol's solution
- description
- This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.
- interventionNames
- Drug: 1.0% Lugol's solution
- type
- EXPERIMENTAL
- label
- 0.8% Lugol's solution
- description
- This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: * patients in the high-risk population of ESCC; * or general risk population of ESCC between 40 to 74 years old. Definition of high-risk population of ESCC is list in supporting information33. Exclusion criteria included the following: * with obvious abnormalities in stomach, confirmed by either white-light endoscopy (WLE) or pCLE, including gastric cancer, acute erosive and hemorrhagic gastritis, chronic atrophic gastritis, H. pylori infection and severe bile reflux gastritis; * advanced esophageal carcinoma; * known esophageal surgery or endoscopic treatment; * known esophageal radiotherapy or chemotherapy; * esophageal stenosis; * food retention; * allergy to iodine or fluorescein sodium; * hyperthyroid; * coagulopathy; * acute bleeding; * severe organ failure; * pregnant or breastfeeding women.
References
Publications (1)
- DERIVEDQu JY, Li Y, Liu GQ, Li Z, Zhong N, Zhang MM, Li YY, Yu T, Lu XF, Li LX, Liu H, Qi QQ, Li YQ, Zuo XL. Optimal concentration of Lugol's solution for detecting early esophageal carcinoma: A randomized controlled trial. J Gastroenterol Hepatol. 2023 Jun;38(6):962-969. doi: 10.1111/jgh.16190. Epub 2023 Apr 24. PMID 37094943